Eligibility

Ages Eligible for Study

18 years to 75 years

Genders Eligible for Study

Both

Keywords

B-cell lymphoma, CHOP, CEOP, and Cardiotoxicity

Sponsors

Other

Fudan University

Inclusion Criteria

- Previously untreated aggressive B-cell lymphoma

- Age range 18-75 years old

- ECOG performance status 0-2

- Life expectancy of more than 3 months

- Adequate organ function

Exclusion Criteria

- Previous serious cardiac disease

- History of other malignancies except cured basal cell carcinoma of skin and carcinoma
in-situ of uterine cervix

- Pregnant or lactating women

- Serious uncontrolled diseases and intercurrent infection

Detailed Description

The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less cardiotoxicity without compromising the efficacy.